What XWPharma does

XWPharma is a clinical-stage biopharmaceutical company founded in 2014 that develops new chemical entities (NCEs) targeting central nervous system disorders, with a focus on sleep and neuropsychiatric conditions. The company applies a proprietary medicinal chemistry platform centered on time-regulated neurobiology to design orally bioavailable, once-daily or once-nightly therapies that aim to retain the efficacy of validated mechanisms while addressing the tolerability, dosing, or formulation limitations of existing treatments. Its clinical pipeline includes valiloxybate (XW10172), an internally discovered GABAB agonist conjugate of oxybate being developed for narcolepsy and sleep disorders in Parkinson's disease (FDA Orphan Drug Designation granted in 2019), and XW10508, an oral once-daily glutamatergic NMDA antagonist/AMPA activator derived from esketamine for treatment-resistant major depressive disorder and chronic pain. XWPharma operates leanly from a Redwood City, California headquarters with additional offices in Wuhan, China and New Taipei City, Taiwan, and has raised approximately $80.5 million across three venture rounds from investors including KPCB China, Elements Capital, WI Harper, Panacea Venture, J&J Innovation, and WuXi AppTec.

XWPharma's business model is a clinical-stage licensing model: it discovers and develops drug candidates through early clinical milestones, then out-licenses global development and commercialization rights to pharmaceutical partners in exchange for upfront payments, development and sales milestones, and tiered royalties. The company does not maintain a commercial sales force, and its revenue is structurally tied to licensing economics rather than product sales. In September 2025, XWPharma executed its most significant commercial transaction to date — an exclusive global license to Avadel Pharmaceuticals for valiloxybate, generating a $20 million upfront payment plus up to $185 million in potential milestones and tiered royalties on net sales. Prior to this, the company had been funded exclusively through venture capital. Its customer base is therefore enterprise pharmaceutical partners rather than end patients, prescribers, or payers.

Name

XWPharma

Legal name

XWPharma Ltd.

Website

https://xwpharma.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

XWPharma is a clinical-stage biopharmaceutical company developing orally bioavailable new chemical entities for sleep and neuropsychiatric CNS disorders, including valiloxybate for narcolepsy and XW10508 for depression and chronic pain, monetizing through licensing deals with pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Clinical-stage CNS biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Clinical-stage biopharmaceutical
• CNS drug discovery
• Neurology therapeutics pipeline
• New chemical entities
• Pharmaceutical licensing deals

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing and milestone payments: XWPharma generates revenue through licensing agreements where partners develop and commercialize its drug candidates. The company receives upfront payments, development milestones, performance-based sales milestones, and tiered royalties. For valiloxybate, Avadel paid $20M upfront with potential for up to $30M in development milestones, up to $155M in sales milestones for net sales up to $750M, plus royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

XWPharma is a clinical-stage biopharmaceutical company that internally discovers and develops novel small-molecule new chemical entities (NCEs) for central nervous system (CNS) disorders, including Valiloxybate/XW10172 (a GABAB agonist for narcolepsy and Parkinson's disease sleep disorders) and XW10508 (an orally bioavailable NMDA antagonist/AMPA activator for treatment-resistant major depressive disorder and chronic pain). The company advances these programs through early clinical development and licenses them to large pharmaceutical partners (e.g., Avadel Pharmaceuticals) for late-stage development, regulatory approval, and commercialization in exchange for upfront payments, milestones, and royalties.

Product overview

XWPharma is a clinical-stage biopharmaceutical company developing a pipeline of novel CNS drug candidates. The company operates a multi-product portfolio approach with two internally discovered new chemical entities: XW10172 (GABAB agonist for narcolepsy and Parkinson's disease sleep disorders) and XW10508 (NMDA antagonist/AMPA activator for depression and chronic pain). A third candidate, Valiloxybate, was licensed to Avadel Pharmaceuticals in September 2025. All therapies apply novel platform chemistry to time-regulated neurobiology.

Differentiator

Problem solved

Functional benefit

Products and services

• Valiloxybate (XW10172 / XWL-008) Internally discovered, investigational GABAB agonist new chemical entity (NCE) developed for the treatment of narcolepsy and non-motor symptoms (sleep disorders) in Parkinson's disease. Valiloxybate is a novel, patented conjugate of oxybate designed for once-at-bedtime dosing with optimal pharmacokinetics — rapid oral absorption, prompt release, and sustained duration at desired plasma concentrations. It is salt-free and artificial sweetener-free, addressing formulation limitations of existing oxybate therapies. Granted FDA Orphan Drug Designation in June 2019 for narcolepsy.
• XW10508 Internally discovered, investigational, orally bioavailable, once-daily glutamatergic new chemical entity providing NMDA receptor inhibition and AMPA receptor activation. Derived from esketamine with extended-release oral formulation, designed to deliver esketamine-like efficacy for treatment-resistant major depressive disorder (MDD) and chronic pain without the transient side effects and administration burden of intranasal or IV esketamine/ketamine.

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Avadel PharmaceuticalsflagshipStrategic or Co-development Partner · 3 September 2025Exclusive global license agreement where Avadel obtained rights to develop and commercialize valiloxybate, a once-at-bedtime, salt-free and artificial sweetener-free oxybate therapy for treating narcolepsy and idiopathic hypersomnia. XWPharma received $20 million upfront payment with potential development milestones up to $30 million, performance-based sales milestones up to $155 million for net sales up to $750 million, and tiered royalties.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Jazz Pharmaceuticals: Markets Xywav (oxybate) and other narcolepsy therapies, generating the bulk of the ~$2B U.S. GABAB narcolepsy market. Directly competes with XWPharma's valiloxybate on mechanism (GABAB agonism) and indication (narcolepsy).
• Avadel Pharmaceuticals: Exclusive global licensee of XWPharma's valiloxybate (September 2025) and developer of Lumryz, an oxybate therapy for narcolepsy. Directly comparable as a narcolepsy-focused commercial-stage peer with overlapping GABAB asset and patient population.
• Harmony Biosciences: Markets Wakix (pitolisant) for narcolepsy and is expanding its CNS pipeline. Comparable as a CNS-focused, U.S.-based biopharma targeting narcolepsy patients — the same primary indication as XWPharma's lead asset.
• Axsome Therapeutics: Commercial CNS company behind Auvelity for major depressive disorder. Closely comparable to XWPharma's XW10508 in target indication (MDD) and strategy of developing differentiated, mechanism-validated CNS therapies.
• Sage Therapeutics: CNS-focused biopharma that developed Zurzuvae for postpartum depression and has additional CNS programs. Comparable in focus on CNS indications with high unmet need and use of differentiated neuroactive mechanisms, similar to XWPharma's platform approach.
• Intra-Cellular Therapies: Develops and commercializes Caplyta for CNS indications including schizophrenia and bipolar depression. Directly comparable as a CNS biopharma addressing neuropsychiatric disorders, now operating under Johnson & Johnson following acquisition.
• Acadia Pharmaceuticals: Markets Nuplazid for Parkinson's disease psychosis and is expanding CNS indications. Directly comparable to XWPharma in CNS focus and overlap on Parkinson's-related indications (XWPharma targets sleep disorders in Parkinson's).
• BioXcel Therapeutics: Clinical-stage CNS biopharma developing therapies for agitation in dementia and other neuropsychiatric conditions. Comparable as a small, clinical-stage CNS peer pursuing differentiated mechanisms in underserved indications.
• Centessa Pharmaceuticals: Clinical-stage biopharma with CNS/sleep programs including orexin-targeting assets. Comparable as a similarly staged, neuroscience-focused peer developing NCEs against validated CNS mechanisms — closely aligned to XWPharma's discovery strategy.

Broad incumbents

• Johnson & Johnson (Janssen): Markets Spravato (esketamine) for treatment-resistant depression, directly competing with XWPharma's XW10508. As a diversified pharma incumbent, J&J is a broader peer but the most relevant comparator for XW10508's NMDA-targeted TRD positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds1 record

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about XWPharma